Pfizer/Napp consider £600m UK cancer fund option after NICE process
This article was originally published in Scrip
Two pharmaceutical firms, Pfizer (Wyeth) and Napp Pharmaceuticals, have decided not to submit any evidence to the UK National Institute for health and Clinical Excellence (NICE) for their respective anticancer drugs leaving the institute to terminate these appraisals and advising NHS bodies to make local decisions for their funding. This will bring the number of such terminations to eight.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.